异位子宫内膜和在位子宫内膜分泌泌乳素的研究

作者将29例子宫内膜异位症（简称异位症）患者的异位和在位内膜进行离体组织孵育，应用放射免疫方法检测孵育液中泌乳素（PRL）含量；同时应用ABC免疫酶标记法确定异位和在位内膜分泌PRL的部位，结果异位和在位内膜离体组织经0～24h孵育，孵育液中PRL含量均显著增加（P＜0．05）；继续孵育至48h，PRL含量不再增加。但异位内膜分泌PRL的活性低于自身在位内膜。免疫组化PRL检测，异位和在位内膜分别有4和6例呈PRL阳性反应。组织学对照现察，内膜成熟上皮细胞数及前蜕膜细胞数越多者，其相应孵育液中PRL含量越高，免疫组化PRL阳性反应也越强。提示异位内膜PRL分泌特点与其自身在位内膜不完全相同，可能与病理环境有关。     

尿路子宫内膜异位症(附3例报告)

目的：重视尿路子宫内膜异位症，探讨其诊断,治疗方法，方法：对3例尿路子宫内膜异位症的临床表现和B超，CT，膀胱镜征象以及治疗方法进行分析。结果：术前明确诊断2例，术中发现1例，术后均病理证实，无复发，痊愈出院，疗效满意。结论：确诊需靠腔镜检查或手术探查，诊断应强调详细地询问病史，治疗方法的选择决定于子宫内膜异位症的部位。     

The relationship between interstitial cystitis and endometriosis in patients with chronic pelvic pain.

OBJECTIVE: This study was designed to determine the relationship between interstitial cystitis (IC), endometriosis (endo), and chronic pelvic pain (CPP) in individuals in whom nongynecological and nonurological problems had been previously ruled out. METHODS: A prospective study of 162 consecutive women with a complaint of chronic pelvic pain seen in the clinic was performed between August 2002 and December 2005. These patients underwent a workup to exclude other causes of pelvic pain, had PUF (Pain Urgency and Frequency) questionnaires filled out, and underwent a laparoscopy and a cystoscopy with hydrodistention. Pain levels were determined, and treatment was reviewed and enumerated. Results were obtained and quantified. RESULTS: In this study, 123 (76%) patients were diagnosed with active endometriosis, 133 (82%) were diagnosed with interstitial cystitis, and 107 (66%) had both disease entities simultaneously. Thirteen (8%) patients were diagnosed with pathologies unrelated to endometriosis and interstitial cystitis. Pain levels were seen to decrease at 6 months in all groups of patients with the exception of those patients with endometriosis only. CONCLUSION: CPP is a difficult, taxing, and frustrating concern for many women in the United States. These individuals have traditionally been difficult to treat. A large number of women with CPP in our patient population have been shown to have endometriosis, interstitial cystitis, or both. Therefore, a workup for premenopausal individuals with CPP involves obtaining a history that keys into possible nongynecologic causes of pain, a complete accounting of urinary problems, and a thorough history of gynecological problems. A physical examination with a comprehensive history should be performed, and the investigation may include the possibility of a simultaneous laparoscopy and cystoscopy if warranted. These procedures can serve as both a means for diagnosis and treatment of these problems when encountered.     

超长方案促性腺激素释放激素激动剂降调节对子宫内膜异位症体外受精-胚胎移植结局的影响

本中心对129例经腹腔镜证实为美国生殖医学会(ASRM)II-IV期子宫内膜异位症(内异症)合并其他不育因素而行体外受精-胚胎移植(IVF-ET)治疗的病例,进行了回顾性统计和分析。一、资料和方法1.临床资料:从2005年4月至2007年3月,在本中心接受IVF-ET治疗经腹腔镜证实为ASRMII-IV期内异症合并其他不育因素的129个周期病例;对照组为输卵管性不育的1,543个周期。内异症组根据有无促性腺激素释放激素激动剂(GnRH-a)药物降调节分为A、B两组进行分析,A组:中重度内异症在手术后接受长效GnRH-a(3.75 mg/支,每28 d一支,共2~6支)抑制治疗的39个…     

阿拉瑞林与小剂量利维爱联合应用治疗子宫内膜异位症合并不孕症的研究

目的:探讨阿拉瑞林与小剂量利维爱(替勃龙)联合应用治疗子宫内膜异位症合并不孕症的疗效及其耐受性。方法:研究对象为1998年1月～2001年6月期间在我院诊治的40例子宫内膜异位症合并不孕症患者。实验组给以阿拉瑞林及利维爱,对照组单用阿拉瑞林。结果:用药后两组患者血清E2、P、FSH、LH水平及AEMAb、CA125阳性率均明显下降;症状体征明显改善;在治疗结束后6个月,实验组中55％、对照组中45％患者妊娠,两组间差异无统计学意义(P>0.05)。实验组未出现低雌激素症候群,而对照组中85％患者出现该症候群,两组差异有统计学意义(P<0.05)。结论:阿拉瑞林与小剂量利维爱联合应用不仅疗效好,而且副作用小。     

通瘀注射液盆腔给药法治疗外在型子宫内膜异位症的临床研究

目的　运用通瘀注射液在非直视下经输卵管盆腔给药对子宫内膜异位症 (EEMs)的治疗作用 ,探讨活血化瘀法对EEMs的作用机理及此给药法的优势。方法　将临床治疗的EEMs患者 60例随机分为治疗组 (通瘀注射液组 )和对照组 (丹那唑组 ) ,疗程各为 3个月。用药前后测定下列指标 :临床症状与体征、内分泌激素、血液流变学、癌抗原 12 5 (CA12 5)和子宫内膜抗体 (EMAb)的阳性率变化。结果　治疗组的临床症状与体征、血液粘滞度和红细胞压积、CA12 5和EMAb的阳性率均降低 ,卵泡刺激素 (FSH)、黄体生成素 (LH)、雌二醇 (E2 )和孕激素 (P)的含量均受到调节 ,与对照组相比 ,差异有显著性。而治疗组对内分泌的调节能力弱于对照组 ,但作用柔和、均衡。结论　通瘀注射液对EEMs的作用是通过清除月经时异位内膜的瘀血、水肿、改善微循环及组织供氧、调节免疫功能和内分泌紊乱而实现的 ,与丹那唑相比其副作用小、并以治本为主。盆腔给药法则可使药物直达病灶 ,见效快     

血清CA125检测对子宫内膜异位症的临床诊断价值

目的 :探讨血清CA12 5测定对术前子宫内膜异位症的诊断价值。方法 :99例子宫内膜异位症经腹手术前测定CA12 5水平 ,并与 90例作对照比较。结果 :子宫内膜异位症CA12 5阳性率 >3 5U /ml,为 5 7.5 7% ,对照组为 8.88% (P <0 .0 1)。内膜异位囊肿高于卵巢囊肿 (P <0 .0 1) ,子宫腺肌病高于子宫肌瘤 (P <0 .0 5 )。结论 :血清CA12 5测定对子宫内膜异位症有较理想的诊断价值 ,对异位囊肿与卵巢囊肿 ,子宫腺肌病与子宫肌瘤有鉴别意义     

子宫内膜异位症患者血清中靶抗体的检测和应用

目的 :建立一种ELISA方法 ,以检测子宫内膜异位症患者血清中抗转铁蛋白抗体。　方法 :用转铁蛋白包被的间接ELISA方法检测血清中的抗转铁蛋白抗体。血清标本来自 96例正常体检女性 ,6 4例妊娠妇女 ,72例儿科女童 ,以及 2 4例子宫内膜异位症患者。　结果 :子宫内膜异位症患者血清中的抗转铁蛋白抗体阳性率远远高于对照组 ,特异性为 99.0 % ,敏感度为 95 .8% ,准确性为 99.2 %。　结论 :子宫内膜异位症患者血清抗转铁蛋白抗体阳性率明显高于对照组 ,抗转铁蛋白抗体检测可作为子宫内膜异位症的非创伤性诊断方法     

子宫内膜异位症患者血清及腹腔液中血小板衍生生长因子、血管细胞粘附分子水平的变化及其意义

目的通过检测子宫内膜异位症(EMs)患者血清及腹腔液中血小板衍生生长因子(PDGF)、血管细胞粘附分子-(VCAM-1)浓度,探讨PDGF和VCAM-1在EMs发病中的作用。方法选取手术后病理证实为EMs的40例患者为EMs组,其中I~II期17例,III~IV23例;非EMs组20例作为对照组。应用酶联免疫吸附法(ELISA)检测血清及腹腔液中PDGF和VCAM-1水平。结果EMs组血清及腹腔液中PDGF、VCAM-1水平均明显高于对照组(P<0.01)。随EMs期别的增加,其血清和腹腔液中PDGF、VCAM-1含量呈上升趋势;EMsIII~IV期水平显著高于I~II期(P<0.05)。EMs患者PDGF与VCAM-1呈正相关性(P<0.05)。结论EMs患者PDGF、VCAM-1表达水平升高,在EMs的发生发展中具有重要作用。     

左炔诺孕酮宫内缓释系统临床应用研究

左炔诺孕酮宫内缓释系统（LNG-IUS）是一种安全、高效的宫内节育器（IUD），其通过每天释放小剂量的左炔诺孕酮至宫腔实现孕激素的非全身给药，从而开辟了在非避孕领域的许多新的应用。现就其在治疗月经过多、子宫内膜异位症和腺肌症、激素替代治疗期间的子宫内膜保护等方面进行综述。